A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Inclusion Criteria:

• Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m ²)

• Are either

• individuals ≥40 years of age with established cardiovascular disease (CVD).

• CVD is defined as meeting at least one of the following:

• Coronary artery disease

• Cerebrovascular disease

• Peripheral arterial disease OR

• individuals without established CVD but have the presence ofcardiovascular (CV) risk factors (primary prevention)

• women 55-69 years of age or men 50-64 years of age with at least 3 riskfactors like tobacco use, dyslipidemia, hypertension at screening, or

• women ≥70 years of age or men, ≥65 years of age with at least 2 riskfactors at screening.

Exclusion Criteria:

• Have type 1 diabetes (T1D) or (T2D), history of ketoacidosis, or hyperosmolarstate/coma

• Have laboratory evidence diagnostic of diabetes mellitus at screening of HbA1c ≥6.5% (≥48 millimole/mole (mmol/mol) or fasting glucose (FG) ≥126 milligram/deciliter (≥7.0 millimole/liter (mmol/L).

• Any one of the following CV conditions within 90 days prior to screening

• MI

• acute coronary syndrome

• stroke

• coronary or peripheral arterial revascularization procedure, which may alsoinclude carotid artery revascularization, or

• acute decompensated heart failure

• Have a known clinically significant gastric emptying abnormality such as severegastroparesis or gastric outlet obstruction or have undergone or currently planningany gastric bypass (metabolic) surgery or restrictive bariatric surgery. Note:Liposuction or abdominoplasty are not considered as gastric bypass procedures.

• Have a history of chronic or acute pancreatitis

• Have a family or personal history of medullary thyroid carcinoma or multipleendocrine neoplasia syndrome type 2.

• Have acute or chronic hepatitis, or clinical signs or symptoms of any other liverdisease, or have elevated liver enzyme measurements, determined by the centrallaboratory at screening

• Have a presence or history of malignant neoplasms within the past 5 years prior toscreening.